Signal breakdowns, filing deep dives, and technical analysis of how our AI agents extract alpha from SEC filings and earnings data.
BioAlpha's AI agents dissected NVIDIA's Q1 2026 earnings call in real-time, surfacing sentiment shifts, guidance language anomalies, and supply chain signals that consensus estimates failed to price in. Here's the full breakdown.
Read analysisSEC 13-F filings reveal exactly what hedge funds, pension funds, and institutional investors are buying and selling. Here's a step-by-step guide to reading them — with a real-world case study on Tesla showing how BioAlpha's AI detects institutional positioning shifts before they become headlines.
Read analysisOur AI agents flagged five biotech stocks where executives and directors are buying shares in the open market at an unusual pace. Insider buying in biotech often precedes clinical trial results, FDA decisions, and partnership announcements. Here's what the data shows.
Read analysisThree days before NVIDIA's Q4 earnings call, our agents detected a convergence of signals across SEC filings, insider transactions, and supply chain data that Wall Street missed entirely.
Read analysisFrom buried goodwill impairments to suspicious revenue recognition changes, here are the five most concerning patterns our AI agents flagged in this week's SEC filings.
Read analysisThe average 10-K is 287 pages. A senior analyst takes 4–6 hours to review one. Our AI agents process it in 90 seconds. Here's the technical architecture behind BioAlpha's filing analysis pipeline.
Read analysisBlog posts are published days after our subscribers receive the signals. Get real-time alerts delivered to your inbox.
Get one free biotech trading signal every week — AI-powered analysis from real SEC filings.